TABLE 2.
Clinical and laboratory data for HEV RNA-positive AHE patients
| Patienta | Age (yr)/sexb | IgG anti-HEV
|
IgM anti-HEV
|
Travel history | Daysd | ||
|---|---|---|---|---|---|---|---|
| Reactivity | O.D.c | Reactivity | O.D. | ||||
| 1 | 35/F | + | 4.102 | + | 0.848 | Mexico | 5 |
| 2 | 38/M | + | 4.141 | + | 1.040 | Philippines | 4 |
| 3 | 67/M | + | 3.560 | + | 1.196 | None | 12 |
| 4 | 57/M | + | 3.726 | + | 0.752 | China | 6 |
| 5 | 72/M | + | 3.882 | + | 0.618 | China | 14 |
| 6 | 31/M | + | 1.375 | − | 0.137 | China | 14 |
| 7 | 74/M | + | 0.950 | − | 0.149 | China | 4 |
| 8 | 60/M | + | 0.474 | − | 0.147 | China | 3 |
| 9 | 65/M | + | 0.857 | − | 0.259 | China | 20 |
| 10 | 48/M | − | 0.043 | − | 0.041 | Indonesia | 14 |
| 11 | 28/F | − | 0.113 | − | 0.053 | None | 1 |
| 12 | 27/M | + | 4.000 | + | 3.108 | NAe | NA |
| 13 | 27/M | + | 4.000 | + | 1.615 | NA | NA |
| 14 | 23/M | + | 4.000 | + | 3.645 | NA | NA |
| 15 | 23/M | + | 4.000 | − | 0.234 | NA | NA |
a
Samples 12 to 15 were obtained from two Nepalese AHE patients. Sample 13 was obtained later than sample 12 from the same Nepalese patient. Samples 14 and 15 came from another Nepalese patient, and sample 15 was obtained 17 days later than sample 14.
b
F, female; M, male.
c
O.D., optical density.
d
Days from occurrence of peak levels of serum alanine transaminase to serum sampling.
e
NA, not available.